Tetrabenazine

Expert Opinion on Pharmacotherapy

Volumn 10, Issue 17, 2009, Pages 2883-2896

  Fasano, Alfonso ^a   Bentivoglio, Anna Rita ^a  

^a CATHOLIC UNIVERSITY   (Italy)

Author keywords

Chorea; Dyskinesias; Dystonia; Huntington's disease; Tardive dyskinesias; Tetrabenazine; Therapy; Tic; Tourette's syndrome

Indexed keywords

APOMORPHINE; CLOZAPINE; HALOPERIDOL; LITHIUM; NEUROLEPTIC AGENT; PLACEBO; RESERPINE; SULPIRIDE; TETRABENAZINE; THIOPROPAZATE; TIAPRIDE;

AKATHISIA; ANXIETY DISORDER; APATHY; CHOREA; CLINICAL TRIAL; COGNITIVE DEFECT; DEPRESSION; DIARRHEA; DIZZINESS; DROWSINESS; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DYSPHAGIA; DYSTONIA; EPIGASTRIC PAIN; EXTRAPYRAMIDAL SYMPTOM; GILLES DE LA TOURETTE SYNDROME; HUMAN; HUNTINGTON CHOREA; HYPERKINESIA; INSOMNIA; MEDICAL LITERATURE; MEDLINE; MOOD DISORDER; MYOCLONUS; NAUSEA AND VOMITING; NONHUMAN; PARKINSONISM; PUBLICATION; REVIEW; SALIVATION DISORDER; SIDE EFFECT; SYSTEMATIC REVIEW; TARDIVE DYSKINESIA; TIC; TREMOR; XEROSTOMIA;

ADRENERGIC UPTAKE INHIBITORS; ANIMALS; DRUG INTERACTIONS; HUMANS; MODELS, ANIMAL; NERVOUS SYSTEM DISEASES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TETRABENAZINE;

EID: 73149122141     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656560903386292     Document Type: Review

References (83)

1. Lende N. Psychosedative effects of tetrabenazine (RO 1-9569) on hyperactive and disturbed mentally retarded patients. Dis Nerv Syst 1960;21(Suppl 3): 118-119
2. Pakkenberg H. The effect of tetrabenazine in some hyperkinetic syndromes. Acta Neurol Scand 1968;44:391-393
3. Mehvar R, Jamali F, Watson MW, et al. Pharmacokinetics of tetrabenazine and its major metabolite in man and rat. Bioavailability and dose dependency studies. Drug Metab Dispos 1987;15:250-255
4. Roberts MS, McLean S, Millingen KS, et al. The pharmacokinetics of tetrabenazine and its hydroxy metabolite in patients treated for involuntary movement disorders. Eur J Clin Pharmacol 1986;29:703-708
5. Roberts MS, Watson HM, McLean S, et al. Determination of therapeutic plasma concentrations of tetrabenazine and an active metabolite by high-performance liquid chromatography. J Chromatogr 1981;226:175-182
6. Jankovic J. Tetrabenazine in the treatment of hyperkinetic movement disorders. Adv Neurol 1983;37:277-289
7. Gonzalez AM, Walther D, Pazos A, et al. Synaptic vesicular monoamine transporter expression: distribution and pharmacologic profile. Brain Res Mol Brain Res 1994;22:219-226
8. Erickson JD, Schafer MK, Bonner TI, et al. Distinct pharmacological properties and distribution in neurons and endocrine cells of two isoforms of the human vesicular monoamine transporter. Proc Natl Acad Sci USA 1996;93:5166-5171
9. Quinn GP, Shore PA, Brodie BB. Biochemical and pharmacological studies of RO 1-9569 (tetrabenazine), a nonindole tranquilizing agent with reserpine-like effects. J Pharmacol Exp Ther 1959;127:103-109
10. Pettibone DJ, Totaro JA, Pflueger AB. Tetrabenazine-induced depletion of brain monoamines: characterization and interaction with selected antidepressants. Eur J Pharmacol 1984;102:425-430
11. Scherman D, Boschi G, Rips R, et al. The regionalization of [3H] dihydrotetrabenazine binding sites in the mouse brain and its relationship to the distribution of monoamines and their metabolites. Brain Res 1986;370:176-181
12. Pearson SJ, Reynolds GP. Depletion of monoamine transmitters by tetrabenazine in brain tissue in Huntington's disease. Neuropharmacology 1988;27:717-719
13. Login IS, Cronin MJ, MacLeod RM. Tetrabenazine has properties of a dopamine receptor antagonist. Ann Neurol 1982;12:257-262
14. Reches A, Burke RE, Kuhn CM, et al. Tetrabenazine, an amine-depleting drug, also blocks dopamine receptors in rat brain. J Pharmacol Exp Ther 1983;225:515-521
15. Pletscher A, Brossi A, Gey K. Benzoquinolizine derivatives: a new class of monoamine decreasing drugs with psychotropic action. Int Rev Neurobiol 1962;4:275-306
16. Burke RE, Reches A, Traub MM, et al. Tetrabenazine induces acute dystonic reactions. Ann Neurol 1985;17:200-202
17. McLellan DL, Chalmers RJ, Johnson RH. A double-blind trial of tetrabenazine, thiopropazate, and placebo in patients with chorea. Lancet 1974;1:104-107
18. Tomlinson DR. The mode of action of tetrabenazine on peripheral noradrenergic nerves. Br J Pharmacol 1977;61:339-344
19. Thibaut F, Faucheux BA, Marquez J, et al. Regional distribution of monoamine vesicular uptake sites in the mesencephalon of control subjects and patients with Parkinson's disease: a postmortem study using tritiated tetrabenazine. Brain Res 1995;692:233-243
20. Mehvar R, Jamali F. Concentration-effect relationships of tetrabenazine and dihydrotetrabenazine in the rat. J Pharm Sci 1987;76:461-465
21. Tang TS, Chen X, Liu J, et al. Dopaminergic signaling and striatal neurodegeneration in Huntington's disease. J Neurosci 2007;27:7899-7910
22. Satou T, Anderson AJ, Itoh T, et al. Repetitive administration of tetrabenazine induces irreversible changes in locomotion and morphology of the substantia nigra in rats. Exp Toxicol Pathol 2001;53:303-308
23. Roze E, Saudou F, Caboche J. Pathophysiology of Huntington's disease: from huntingtin functions to potential treatments. Curr Opin Neurol 2008;21:497-503
24. Phillips W, Shannon KM, Barker RA. The current clinical management of Huntington's disease. Mov Disord 2008;23:1491-1504
25. Leonard DP, Kidson MA, Brown JG, et al. A double blind trial of lithium carbonate and haloperidol in Huntington's chorea. Aust NZ J Psychiatry 1975;9:115-118
26. Caine ED, Polinsky RJ, Kartzinel R, et al. The trial use of clozapine for abnormal involuntary movement disorders. Am J Psychiatry 1979;136:317-320
27. Roos RA, Buruma OJ, Bruyn GW, et al. Tiapride in the treatment of Huntington's chorea. Acta Neurol Scand 1982;65:45-50
28. Quinn N, Marsden CD. A double blind trial of sulpiride in Huntington's disease and tardive dyskinesia. J Neurol Neurosurg Psychiatry 1984;47:844-847
29. Deroover J, Baro F, Bourguignon RP, et al. Tiapride versus placebo: a double-blind comparative study in the management of Huntington's chorea. Curr Med Res Opin 1984;9:329-338
30. van Vugt JP, Siesling S, Vergeer M, et al. Clozapine versus placebo in Huntington's disease: a double blind randomised comparative study. J Neurol Neurosurg Psychiatry 1997;63:35-39
31. Berardelli A, Noth J, Thompson PD, et al. Pathophysiology of chorea and bradykinesia in Huntington's disease. Mov Disord 1999;14:398-403
32. Kingston D. Tetrabenazine for involuntary movement disorders. Med J Aust 1979;1:628-630
33. Jankovic J, Orman J. Tetrabenazine therapy of dystonia, chorea, tics, and other dyskinesias. Neurology 1988;38:391-394
34. Asher SW, Aminoff MJ. Tetrabenazine and movement disorders. Neurology 1981;31:1051-1054
35. Ondo WG, Tintner R, Thomas M, et al. Tetrabenazine treatment for Huntington's disease-associated chorea. Clin Neuropharmacol 2002;25:300-302
36. Huntington Study Group. Tetrabenazine as antichorea therapy in Huntington disease: a randomized controlled trial. Neurology 2006;66:366-372
37. Frank S, Ondo W, Fahn S, et al. A study of chorea after tetrabenazine withdrawal in patients with Huntington disease. Clin Neuropharmacol 2008;31:127-33
38. Jankovic J, Beach J. Long-term effects of tetrabenazine in hyperkinetic movement disorders. Neurology 1997;48:358-362
39. Kenney C, Hunter C, Jankovic J. Long-term tolerability of tetrabenazine in the treatment of hyperkinetic movement disorders. Mov Disord 2007;22:193-197 (Pubitemid 46374760)
40. Fasano A, Cadeddu F, Guidubaldi A, et al. The long-term effect of tetrabenazine in the management of Huntington disease. Clin Neuropharmacol 2008;31:313-318
41. Mahant N, McCusker EA, Byth K, et al. Huntington's disease: clinical correlates of disability and progression. Neurology 2003;61:1085-1092
42. Pasricha PJ, Pehlivanov N, Sugumar A, et al. Drug insight: from disturbed motility to disordered movement-a review of the clinical benefits and medicolegal risks of metoclopramide. Nat Clin Pract Gastroenterol Hepatol 2006;3:138-148
43. Stacy M, Cardoso F, Jankovic J. Tardive stereotypy and other movement disorders in tardive dyskinesias. Neurology 1993;43:937-941
44. Halliday J, Farrington S, Macdonald S, et al. Nithsdale Schizophrenia Surveys 23: movement disorders. 20-year review. Br J Psychiatry 2002;181:422-427
45. Kazamatsuri H, Chien C, Cole JO. Treatment of tardive dyskinesia. I. Clinical efficacy of a dopamine-depleting agent, tetrabenazine. Arch Gen Psychiatry 1972;27:95-99
46. Kazamatsuri H, Chien CP, Cole JO. Long-term treatment of tardive dyskinesia with haloperidol and tetrabenazine. Am J Psychiatry 1973;130:479-483
47. Ondo WG, Hanna PA, Jankovic J. Tetrabenazine treatment for tardive dyskinesia: assessment by randomized videotape protocol. Am J Psychiatry 1999;156:1279-1281
48. Stacy M, Jankovic J. Tardive tremor. Mov Disord 1992;7:53-57
49. Storey E, Lloyd J. Tardive tremor. Mov Disord 1997;12:808-810
50. Leckman JF. Tourette's syndrome. Lancet 2002;360:1577-1586
51. Sweet RD, Bruun R, Shapiro E, et al. Presynaptic catecholamine antagonists as treatment for Tourette syndrome. Effects of alpha methyl para tyrosine and tetrabenazine. Arch Gen Psychiatry 1974;31:857-861
52. Jankovic J, Glaze DG, Frost JD Jr. Effect of tetrabenazine on tics and sleep of Gilles de la Tourette's syndrome. Neurology 1984;34:688-692
53. Jankovic J, Rohaidy H. Motor, behavioral and pharmacologic findings in Tourette's syndrome. Can J Neurol Sci 1987;14:541-546
54. Paleacu D, Giladi N, Moore O, et al. Tetrabenazine treatment in movement disorders. Clin Neuropharmacol 2004;27:230-233
55. Jankovic J. Treatment of hyperkinetic movement disorders with tetrabenazine: a double-blind crossover study. Ann Neurol 1982;11:41-47
56. Marsden CD, Harrison MJ. Idiopathic torsion dystonia (dystonia musculorum deformans). A review of forty-two patients. Brain 1974;97:793-810
57. Marsden CD, Marion MH, Quinn N. The treatment of severe dystonia in children and adults. J Neurol Neurosurg Psychiatry 1984;47:1166-1173
58. Mariotti P, Fasano A, Contarino MF, et al. Management of status dystonicus: our experience and review of the literature. Mov Disord 2007;22:963-968
59. Scott BL. Evaluation and treatment of dystonia. South Med J 2000;93:746-751
60. Hoehn MM, Cherington M. Spinal myoclonus. Neurology 1977;27:942-946
61. Jankovic J, Pardo R. Segmental myoclonus. Clinical and pharmacologic study. Arch Neurol 1986;43:1025-1031
62. Chatterjee A, Frucht SJ. Tetrabenazine in the treatment of severe pediatric chorea. Mov Disord 2003;18:703-706
63. Kenney C, Jankovic J. Tetrabenazine in the treatment of hyperkinetic movement disorders. Expert Rev Neurother 2006;6:7-17
64. Kenney C, Hunter C, Mejia N, et al. Is history of depression a contraindication to treatment with tetrabenazine? Clin Neuropharmacol 2006;29:259-264
65. Gimenez-Roldan S, Mateo D. Huntington disease: tetrabenazine compared to haloperidol in the reduction of involuntary movements. Neurologia 1989;4:282-287
66. Kidd DW, McLellan DL. Self-poisoning with tetrabenazine. Br J Clin Pract 1972;26:179-180
67. Stevens E, Roman A, Houa M, et al. Severe hyperthermia during tetrabenazine therapy for tardive dyskinesia. Intensive Care Med 1998;24:369-371
68. Burke RE, Fahn S, Mayeux R, et al. Neuroleptic malignant syndrome caused by dopamine-depleting drugs in a patient with Huntington disease. Neurology 1981;31:1022-1025
69. Mateo D, Munoz-Blanco JL, Gimenez-Roldan S. Neuroleptic malignant syndrome related to tetrabenazine introduction and haloperidol discontinuation in Huntington's disease. Clin Neuropharmacol 1992;15:63-68
70. Ossemann M, Sindic CJ, Laterre C. Tetrabenazine as a cause of neuroleptic malignant syndrome. Mov Disord 1996;11:95
71. Petzinger GM, Bressman SB. A case of tetrabenazine-induced neuroleptic malignant syndrome after prolonged treatment. Mov Disord 1997;12:246-248
72. Huang CY, McLeod JG, Holland RT, et al. Tetrabenazine in the treatment of Huntington's chorea. Med J Aust 1976;1:583-584
73. Mestre T, Ferreira J, Coelho MM, et al. Therapeutic interventions for symptomatic treatment in Huntington's disease. Cochrane Database Syst Rev 2009;CD006456
74. Bonelli RM, Wenning GK. Pharmacological management of Huntington's disease: an evidence-based review. Curr Pharm Des 2006;12:2701-2720
75. Brusa L, Orlacchio A, Moschella V, et al. Treatment of the symptoms of Huntington's disease: preliminary results comparing aripiprazole and tetrabenazine. Mov Disord 2009;24:126-129
76. Rauchverger B, Isakov V, Jabarin M. Olanzapine-induced tardive dystonia successfully treated by tetrabenazine. J Neuropsychiatry Clin Neurosci 2007;19:484-485
77. Zaidi SH, Faruqui RA. Aripiprazole is associated with early onset of Tardive Dyskinesia like presentation in a patient with ABI and psychosis. Brain Inj 2008;22:99-102
78. Fasano A, Mazzone P, Piano C, et al. GPi-DBS in Huntington's disease: results on motor function and cognition in a 72-year-old case. Mov Disord 2008;23:1289-1292
79. Kenney C, Hunter C, Davidson A, et al. Short-term effects of tetrabenazine on chorea associated with Huntington's disease. Mov Disord 2007;22:10-13
80. Watson MW, Skelton D, Jamali F. Treatment of tardive dyskinesia: preliminary report on use of tetrabenazine. Can J Psychiatry 1988;33:11-13
81. Shapiro AK, Shapiro AS, Bruun R. Gilles de la Tourette Syndrome. NY: Raven Press; 1978
82. Kenney C, Hunter C, Mejia N, et al. Tetrabenazine in the treatment of Tourette syndrome. J Pediatric Neurol 2007;5:9-13
83. Jankovic J. Dystonia: medical therapy and botulinum toxin. Adv Neurol 2004;94:275-286